atai Life Sciences marks milestone quarter with key clinical wins, Beckley merger plans
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has reflected on a “transformational” first half of 2025, marked by a series of clinical and corporate milestones, including positive topline data from its Phase 2b trial of BPL-003 for treatment-resistant depression. The randomized, quadruple-masked global study enrolled 193 patients and met its primary and all key secondary endpoints.
Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus
Despite the phase 2b failure of inidascamine for CIAS, I maintain a Buy on Atai due to its diversified psychedelic pipeline. Beckley Psytech's BPL-003 drug for treatment-resistant depression showed strong phase 2b results, with rapid and sustained efficacy, and could be phase 2 program with FDA allowance. The pending merger with Beckley Psytech and upcoming catalysts, including FDA meetings and OLE study data, offer significant upside potential.
atai eyes 2025 catalysts in psychedelic portfolio following Recognify trial update
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said on Friday that its platform company, Recognify Life Sciences, reported top-line results from a Phase 2b trial of inidascamine in cognitive impairment associated with schizophrenia (CIAS), which did not meet the primary endpoint but demonstrated consistent signs of cognitive and functional benefit and maintained a favorable safety profile. The double-blind, placebo-controlled study enrolled 242 patients and tested two doses of inidascamine over a six-week treatment period.
atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why
atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
atai Life Sciences price target boosted on robust BPL-003 mid-stage trial results
The atai Life Sciences (NASDAQ:ATAI, ETR:9VC) story has become more attractive following the release of robust Phase 2b trial results for BPL-003 in treatment-resistant depression, analysts at Jefferies believe. BPL-003, an intranasal formulation of DMT developed in partnership in Beckley Psytech, demonstrated rapid, robust and durable antidepressant effects with a single dose.
Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD
Atai Life Sciences' BPL-003 showed robust, rapid, and durable antidepressant effects in Phase 2b TRD data, spiking shares over 20%. BPL-003's short clinic time and strong efficacy could fit existing treatment paradigms, potentially rivaling J&J's Spravato if regulatory hurdles are cleared. Regulatory approval remains uncertain due to controlled substance scheduling, but Atai's differentiated pipeline and patent position offer significant long-term upside.
Atai and Beckley Psytech hail DMT trial results in treatment-resistant depression
Atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced positive topline results from its Phase 2b clinical study in patients with treatment-resistant depression, and a private placement for gross proceeds of $50 million. The clincial study, in partnership with Beckley Psytech, is evaluating BPL-003, a formulation of the psychedelic compound mebufotenin, also known as DMT, that is administered using a nasal spray.
Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?
Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
Psychedelics regain momentum in 2025 on political tailwinds, clinical wins
The psychedelics sector is experiencing a resurgence of optimism in 2025 driven by a more favorable federal government under President Donald Trump's administration, shifting state-level policies, and encouraging clinical trial results supporting the efficacy of psychedelic therapies. A major setback for the sector was the Food and Drug Administration rejecting Lykos Therapeutics' MDMA-assisted therapy for post-traumatic stress disorder in August last year.
FDA seen likely to grant emergency use authorizations for psychedelics, boosting sector stocks
The Food and Drug Administration (FDA) may soon issue emergency use authorizations for psychedelic substances like psilocybin, proponents of psychedelic therapy believe, amid a shit in attitude towards psychedelic therapies under the Trump administration. Emergency use authorizations (EUAs) are considered a more likely near-term regulatory pathway for psychedelics such as psilocybin because, unlike full FDA approval, they require a lower standard of evidence, a report from health-oriented news website Stat published on Wednesday highlighted.
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V.
Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors?
